• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Grove Inc.

    2/10/22 5:01:03 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRVI alert in real time by email
    SC 13G 1 grvi_sc13g.htm SC 13G grvi_sc13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
    § 240.13d-1(b), (c), and (d) and AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

     

    (Amendment No. ____)*

     

    Grove, Inc.

    (Name of Issuer)

       

    Common Stock

    (Title of Class of Securities)

     

    39959A106

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

     

     

     

    ☒

    Rule 13d-1(c)

     

     

     

     

    ☐

    Rule 13d-1(d)

    ____________ 

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 2 of 5 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Jeffrey Bishop

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

      

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

      

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

      

    USA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    1,262,867

    6.

    SHARED VOTING POWER

        

    - 0 -

    7.

    SOLE DISPOSITIVE POWER

      

    1,262,867

    8.

    SHARED DISPOSITIVE POWER

     

    - 0 -

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,262,867

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

      

    7.71% (1)

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    (1) Based on 16,378,006 shares of Common Stock as reported in the Issuer’s quarterly report as filed with the Commission on November 15, 2021.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 3 of 5 Pages

     

    Item 1.

     

     

     

     

     

     

    (a)

    Name of Issuer: Grove, Inc.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices:

     

     

     

     

     

    1710 Whitney Mesa Drive

    Henderson, NV 89014

       

    Item 2.

     

     

     

     

     

     

    (a)

    Name of Person Filing: Jeffrey Bishop

     

     

     

     

    (b)

    Address of Principal Business Office or, if none, Residence:

     

     

     

     

     

    18 Sackett Rd.

    Lee NH 09861

     

     

    (c)

    Citizenship or Place of Organization: United States of America

     

     

     

     

    (d)

    Title of Class of Securities: Common Stock

     

     

     

     

    (e)

    CUSIP Number:

     

    Item 3.

    If this statement is filed pursuant to § 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

     

    (a)

    ☐

    Broker or dealer registered under Section 15 of the Act.

     

     

     

     

     

    (b)

    ☐

    Bank as defined in Section 3(a)(6) of the Act.

     

     

     

     

     

    (c)

    ☐

    Insurance company as defined in Section 3(a)(19) of the Act.

     

     

     

     

     

    (d)

    ☐

    Investment company registered under Section 8 of the Investment Company Act of 1940.

     

     

     

     

     

    (e)

    ☐

    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ☐

    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

     

     

     

     

    (i)

    ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

     

     

     

     

    (j)

    ☐

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

     

     

     

     

    (k)

    ☐

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________________.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 4 of 5 Pages

     

    Item 4.

    Ownership.

     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

       

     

    (a)

    Amount beneficially owned: 1,262,867

     

     

     

     

    (b)

    Percent of class: 7.71% (1)

     

     

     

     

    (c)

    Number of shares as to which the person has:

     

     

    (i)

    Sole power to vote or to direct the vote: 1,262,867

     

     

     

     

    (ii)

    Shared power to vote or to direct the vote: - 0 -

     

     

     

     

    (iii)

    Sole power to dispose or to direct the disposition of: 1,262,867

     

     

     

     

    (iv)

    Shared power to dispose or to direct the disposition of: - 0 -

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

       

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

     

     

    Not Applicable.

       

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security

     

    Being Reported on by the Parent Holding Company or Control Person.

     

     

     

    Not Applicable.

       

    Item 8.

    Identification and Classification of Members of the Group.

     

     

     

    Not Applicable.

       

    Item 9.

    Notice of Dissolution of Group.

     

     

     

    Not Applicable.

       

    Item 10.

    Certifications.

     

     

     

    Not Applicable.

       

     

     

        

    CUSIP No. 39959A106

    13G

    Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    2/10/2022

     

     

    (Date)

     

     

     

     

     

    /s/ Jeffrey Bishop 

     

     

    (Signature)

     

     

     

     

     

     Jeffrey Bishop

     

     

    (Name/Title)

     

     

    Attention: Intentional misstatements or omissions of fact constitute federal criminal violations ( see 18 U.S.C. 1001).

     

     

     

    Get the next $GRVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRVI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRVI
    SEC Filings

    View All

    Grove Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    12/15/22 4:05:24 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Grove Inc.

    EFFECT - UPEXI, INC. (0001775194) (Filer)

    12/5/22 12:15:12 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grove Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    12/2/22 9:15:45 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Marshall Allan bought $63,909 worth of shares (17,303 units at $3.69), increasing direct ownership by 0.68% to 2,575,081 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    1/11/23 4:56:21 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Marshall Allan bought $49,320 worth of shares (12,000 units at $4.11), increasing direct ownership by 0.47% to 2,557,778 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/13/22 5:48:52 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Marshall Allan bought $73,161 worth of shares (18,475 units at $3.96), increasing direct ownership by 0.73% to 2,545,778 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/5/22 3:24:06 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Grove, Inc. Announces Name and Symbol Change to Upexi, Inc. "UPXI"

    HENDERSON, Nev., Aug. 17, 2022 /PRNewswire/ -- Grove Inc. (NASDAQ:GRVI), a market leader in Amazon and eCommerce brand ownership and aggregation, announces that today, August 17, 2022, its trading name on the Nasdaq officially changed from "Grove Inc." to "Upexi, Inc." and its ticker symbol changed from "GRVI" to "UPXI". This accompanies previous press releases notifying investors of this change. CEO Allan Marshall stated, "Last month, we announced our growth strategy in a letter to shareholders that focused on our acquisition plan to bring more, profitable eCommerce brands in various industries under our umbrella. Moving to a new name and stock ticker is a reflection of the progress we have

    8/17/22 4:05:00 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sidoti's August Micro-Cap Virtual Conference

    Presentation Times and Weblinks Released for Over 50 Presenting CompaniesWednesday and Thursday, August 17-18, 2022NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022. The links can also be found at www.sidoticonference.com/events.Presentation AgendaWednesday, August 17th, 2022 (Day 1)*All Times EDT8:30-9:00Mativ Holdings, Inc. (MATV)Brenmiller Energy, Ltd. (BNRG)Sify Technologies Ltd (SIFY)9:15-9:45MISTRAS Group (MG)Bassett Furniture (BSET)Silvercrest Asset Management Group (SAMG)10:00-10:30Anebulo Pharmaceuticals (ANEB)*****

    8/16/22 3:00:00 PM ET
    $AIRI
    $ANEB
    $APRN
    Military/Government/Technical
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Update: Grove, Inc. to Present at Sidoti August Microcap Conference

    HENDERSON, NV , Aug. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove Inc. (GRVI) announced today that Allan Marshall, Chief Executive Officer, is scheduled to present virtually at the Sidoti & Company, August Virtual Microcap Conference on Wednesday, August 17, 2022 at 3:15 pm ET. The presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/WN_FqCzxA3xTbOsMXr-Ml5X7Q Grove will also host virtual one-on-ones with investors throughout the conference.  To register for the presentation of a one-on-one meeting, visit https://www.sidoti.com/events/august-micro-cap-virtual-conference. Registration is free and you are not required to be a Sidoti & Company client. 

    8/10/22 10:56:39 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Financials

    Live finance-specific insights

    View All

    Grove, Inc. Announces Fiscal Year 2021 Audited Financial Results

    Revenues Reach $24.1 Million, a 250% Increase Over 2020 Net Earnings of $2.9 Million or $.25 Per Share HENDERSON, NV, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove, Inc. (NASDAQ:GRVI) ("Grove" or the "Company"), a global innovator in hemp, health, and wellness, today announced audited financial results for its fiscal year ended June 30, 2021 which surpassed preliminary results issued on June 28, 2021.   Investors are encouraged to read the Company's annual report on Form 10-K which was filed with the Securities and Exchange Commission (the "SEC"), contains additional information, and is posted at https://groveinc.io/ Financial Highlights $2

    9/29/21 8:00:00 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:08:22 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:07:48 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:07:14 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care